loader

rad:au

LATEST ARTICLES
Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart
Biotech Investing

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart

RAD receives IND approval from US FDA for Betabart (RV-01)
Biotech Investing

RAD receives IND approval from US FDA for Betabart (RV-01)

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Biotech Investing

Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia
Biotech Investing

Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹?¹Tb-KLK3-mAb Phase I Clinical Trial in Australia

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Biotech Investing

Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Biotech Investing

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors
Biotech Investing

Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Biotech Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake
Biotech Investing

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Biotech Investing

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177
biotech investing

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
biotech investing

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee

Latest News

More News

Outlook Reports

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES